Au Sénégal, près de deux millions de filles et de femmes ont subi des MGF. Au total, 25 % des filles et des femmes ont subi cette pratique, allant de plus de 90 % dans la région de Kédougou à un peu moins de 1 % dans celle de Diourbel
orientations provisoires, 14 juin 2021
L’année 2020 a été une année particulièrement difficile pour la population de la République démocratique du Congo (RDC). Les conflits armés, les épidémies, les catastrophes naturelles ainsi que l’impact socio-économique de la COVID-19 ont considérablement exacerbé les vulnérabilit...s déjà existantes dans un contexte marqué par un manque criant d’accès aux services essentiels pour une grande majorité de la population. La RDC, le plus grand pays d'Afrique subsaharienne et le troisième le plus peuplé, avec une population estimée à 103 millions, demeure confrontée à l'une des crises humanitaires les plus graves au monde.
more
This brief summarizes current evidence and guidance for maintaining safe and effective care across the spectrum of maternal, newborn and infant care while protecting mother and child and health care providers during COVID-19. Furthermore, implications of the principle of “do no harm” are reviewe...d for maternal, newborn and infant care delivery during COVID-19, so that this information is conveniently and readily available to clinical and health system policy leaders and stakeholders in countries and communities. Additionally, considerations for safe oxygen delivery as well as key Infection Prevention and Control (IPC) measures at home and in healthcare facilities for pregnant women, newborns and children are described in detail in the brief.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
The purpose of the toolkit is to bring together existing learning and guidance as a starting point for stakeholders to begin SRH preparedness work. Within the SRH sector the field of preparedness is relatively new and growing. More collective effort is required to further evaluate the impact of prep...aredness efforts and push the field forward. This effort is a first attempt at a draft guidance for SRH preparedness, and is intended for field testing. The toolkit recognizes the longstanding work of the field of emergency and disaster risk management, and endeavors to bridge that work with the human rights-oriented and peoplecentered field of sexual and reproductive health.
more
Hendra virus (HeV) continues to pose a serious public health concern as spillover events occur sporadically. Terminally ill horses can exhibit a range of clinical signs including frothy nasal discharge, ataxia or forebrain signs. Early signs, if detected, can include depression, inappetence, colic o...r mild respiratory signs. All unvaccinated ill horses in areas where flying foxes exist, may potentially be infected with HeV, posing a significant risk to the veterinary community. Equivac® HeV vaccine has been fully registered in Australia since 2015 (and under an Australian Pesticides and Veterinary Medicines Authority special permit since 2012) for immunization of horses against HeV and is the most effective and direct solution to prevent disease transmission to horses and protect humans. No HeV vaccinated horse has tested positive for HeV infection. There is no registered vaccine to prevent, or therapeutics to treat, HeV infection in humans. Previous equine HeV outbreaks tended to cluster in winter overlapping with the foaling season (August to December), when veterinarians and horse owners have frequent close contact with horses and their bodily fluids, increasing the chance of zoonotic disease transmission. The most southerly case was detected in 2019 in the Upper Hunter region in New South Wales, which is Australia's Thoroughbred horse breeding capital. Future spillover events are predicted to move further south and inland in Queensland and New South Wales, aligning with the moving distribution of the main reservoir hosts. Here we (1) review HeV epidemiology and climate change predicted infection dynamics, (2) present a biosecurity protocol for veterinary clinics and hospitals to adopt, and (3) describe diagnostic tests currently available and those under development. Major knowledge and research gaps have been identified, including evaluation of vaccine efficacy in foals to assess current vaccination protocol recommendations.
more
While “sustainability” has become a central aspect of social action and responsibility around the world, its complex and multi-di-
mensional nature requires further explanation.
The African Development Bank has launched a consultation process with health ministers and other partners as it develops a strategy to drive enhanced access to health services across Africa through 2030.
Input from ministers in the Bank’s 54 regional member countries, development partners and c...ivil society is expected to strengthen the Bank’s Strategy for Quality Health Infrastructure in Africa (2021-2030). A robust scoping study titled “Good Health and Well-being” underpins the strategy.
more
This document draws on scientific evidence from the COVID-19 pandemic and from prior public health research on behaviour change, with the purpose of empowering African Union Member States to promote widespread adoption of masks in the general population. This document complements existing Africa CDC... technical guidance on the community use of face masks.
more
Updated 10 August 2020
This document presents an essential medicines list (EML) to manage patients in intensive care units (ICUs) with suspected or confirmed COVID-19 diagnosis, which includes active ingredients with dosage form and concentration, and are preferably in the WHO Model Lists of Essent...ial Medicines 2019; based on clinical presentations and symptoms identified and prioritized in World Health Organization (WHO) and Surviving Sepsis Campaign (SSC) guidelines and the evidence presented in these guidelines.
more
Accessed on 20.10.2020
L͛analyse des tendances récentes montre que le Burkina Faso a enregistré une réduction significative de la mortalité infanto-juvénile. Même si aucune des cibles des OMD 4 et 5 n͛a été atteinte par le pays, le taux de mortalité infanto-juvénile est passé de 129 ...pour mille naissances vivantes en 2010 à 82 pour mille naissances
vivantes en 2015, soit une baisse de 7.3% par an. Ceci est en grande partie dû aux progrès enregistrés en matière de lutte contre la mortalité au bénéfice de la tranche juvénile (de 1 à 4 ans). Cependant, comme près de la moitié des enfants âgés de moins de cinq ans continuent de mourir au cours de leur première
année de vie, il reste beaucoup à faire pour l͛atteinte de la vision globale d͛élimination de la mortalité infanto-juvénile évitable et de réduction de la mortalité des mères comme partie prenante des Objectifs de Développement Durable (ODD).
more
Le Plan de réponse humanitaire (PRH) 2020 a été révisé et publié en mai 2020 afin d’intégrer l’impact de l’épidémie de COVID-19 sur les besoins humanitaires existants et sur les activités des partenaires humanitaires.
Une note d'orientation interagencesur la collaboration avec les communautés des zones à forte densité pour planifier des approches locales de prévention et de gestion de la COVID-19.
The WHO Global Health Estimates show that nearly half a million deaths (493 471) occurred in the WHO European Region due to violence and injuries in 2016. This represents a decline of 29% from 2000. Injuries account for 5.3% of all deaths and 9.6 of all years of life lost. They are a leading cause o...f death in people aged 15–29 years and the second leading cause of death for young people aged 5–14. The three leading causes of injury deaths are self-directed violence (141 089), falls (83 325) and road-traffic injuries (78 198). Inequalities in injury deaths exist in the Region, with mortality rates 2.4 times higher in males than in females and 1.5 times higher in middle-income compared to high-income countries.
more
Un Plan humanitaire multisectoriel spécifique à la réponse COVID-19 a été développé en avril 2020 et constitue un Addendum au Plan de réponse humanitaire 2020 (PRH) afin d’intégrer l’impact de la pandémie de COVID-19 sur les besoins humanitaires existants et sur les activités des part...enaires humanitaires en République Démocratique du Congo (RDC).
more
Migrants in Central Asia and the Russian Federation, have been among the most severely impacted by the COVID-19 pandemic.
In the short term, IOM aims at providing support to migrants who are stranded in countries of destination. In addition, IOM will focus its efforts on addressing data gaps, enhan...cing national and community preparedness, response and recovery efforts, ensuring that affected people have access to basic services, commodities and protection as well as mitigating the socioeconomic impact of COVID-19.
more